Very High Risk Prostate Carcinoma
2 clinical trials · Condition
◉ Watch Very High Risk Prostate Carcinoma
| Record | Firm | Date |
|---|---|---|
| Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer (NCT06388369) | University Hospital, Essen | 2025-08-25 |
| Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 (NCT07054346) | Thomas Hope | 2025-07-08 |
Track Very High Risk Prostate Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.